Who are Evaxion A/S's main suppliers?

Evaxion A/S (EVAX) key suppliers include: PHARMAJET-INC, STATENS-SERUM-INSTITUT, BioNTech SE, BioNTech SE, Johnson & Johnson and 5 more. View the full supplier network at chainsifter.com/chain/EVAX.

Who are Evaxion A/S's major customers?

Evaxion A/S (EVAX) key customers include: BioNTech SE, BioNTech SE, Johnson & Johnson, Johnson & Johnson, Merck & Co., Inc. and 3 more. View the full customer network at chainsifter.com/chain/EVAX.

What sector is Evaxion A/S in?

Evaxion A/S (EVAX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

EVAX Supply Chain: Evaxion A/S Supplier List & 19 Relationships

10Suppliers

8Customers

1Debt Items

20Related Chains

Evaxion A/S Suppliers

Ticker	Name	Confidence	Evidence
PHARMAJET-INC	PHARMAJET-INC	90%	We have entered into license agreements, including with Statens Serum Institut (SSI) and PharmaJet, Inc., to obtain rights to intellectual property useful for pharmaceutical formulations and delivery…
STATENS-SERUM-INSTITUT	STATENS-SERUM-INSTITUT	90%	We have entered into license agreements, including with Statens Serum Institut (SSI) and PharmaJet, Inc., to obtain rights to intellectual property useful for pharmaceutical formulations and delivery…
BNTX	BioNTech SE	72%	ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Prior to any out-licensing commercialization of EVX-01, we are not required to make…
BNTX	BioNTech SE	72%	Reciprocal relationship from BNTX graph: Reciprocal relationship from EVAX graph: ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. P…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from EVAX graph: ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Pr…
JNJ	Johnson & Johnson	72%	ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Prior to any out-licensing commercialization of EVX-01, we are not required to make…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from EVAX graph: bstantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clin…
MRK	Merck & Co., Inc.	72%	bstantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clinical trials. In the event of unstable markets and unfavorable market conditions, …
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX graph: ing income in the mid double-digi…
SNYNF	Sanofi	72%	ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Prior to any out-licensing commercialization of EVX-01, we are not required to make…

Evaxion A/S Customers

Ticker	Name	Confidence	Evidence
BNTX	BioNTech SE	72%	drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholder…
BNTX	BioNTech SE	72%	Reciprocal relationship from BNTX graph: Reciprocal relationship from EVAX graph: drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from EVAX graph: drugs, has become intense. As a resul…
JNJ	Johnson & Johnson	72%	drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholder…
MRK	Merck & Co., Inc.	72%	bstantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clinical trials. In the event of unstable markets and unfavorable market conditions, …
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from EVAX graph: bstantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clin…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX graph: drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. I…
SNYNF	Sanofi	72%	drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholder…

Evaxion A/S Debt Obligations

Instrument	Description	Confidence	Evidence
EVAX-DEBT	Debt stack $7.5M	90%	Market cache reports total debt of $7.5M.

Evaxion A/S Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Evaxion A/S.

Evaxion A/S Ownership

Holder	Name	Confidence	Evidence
EVAX-OWNER-IKARIAN-CAPITAL-LLC	Ikarian Capital, LLC	90%	13F overlay lists Ikarian Capital, LLC as top holder; 16 tracked holders.

Evaxion A/S Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ENLV	Enlivex Ltd.	100.00	2
IBRX	ImmunityBio, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
TBPH	Theravance Biopharma, Inc.	100.00	2
HIMS	Hims & Hers Health, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
BNTX	BioNTech SE	100.00	1	['customer', 'supplier']
CANF	Can-Fite BioPharma Ltd.	100.00	2
PSNL	Personalis, Inc.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
BNBX	BNB Plus Corp.	100.00	2
IBIO	iBio, Inc.	100.00	2

Evaxion A/S Supply Chain